What's Going On With GT Biopharma Stock Tuesday?

Zinger Key Points
  • GT Biopharma enters into a definitive securities purchase agreement for the purchase and sale of 740,000 shares of its common stock.
  • The company anticipates raising approximately $3.2 million from the direct offering.
Loading...
Loading...

GT Biopharma GTBP shares rose Tuesday morning before pulling back and turning negative after the company announced a direct offering.

The Details: GT Biopharma entered into a definitive securities purchase agreement for the purchase and sale of 740,000 shares of its common stock at a purchase price of $4.35 per share. The shares will be offered in a registered direct offering priced at-the-market under Nasdaq rules. Roth Capital Partners is acting as the exclusive placement agent for the offering.

In a concurrent private placement, the company announced it will issue warrants allowing the purchase of up to 740,000 shares of its common stock. The warrants will be immediately exercisable at a price of $4.35 per share and will be valid for five years from issuance.

Before deducting the placement agent’s fees and other expenses, the company anticipates raising approximately $3.2 million. GT Biopharma noted that it plans to use the proceeds for general corporate purposes. The offering is expected to close on or about May 23.

Related Link: AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion

GTBP Price Action: GT Biopharma shares were halted on the circuit breaker Tuesday morning. The stock was down 22.1% at $6.07 at the time of writing, per Benzinga Pro.

Image: 761599 from Pixabay.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsOfferingsMoverswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...